One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

April 29, 2016

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration during the week of April 25, 2016, a decision from the FDA is expected in early 2017.…


Ipsen Partners with CCF and Self Care Catalysts to Provide Free Support App for Neuroendocrine Tumor Patients

April 6, 2016

Ipsen Biopharmaceuticals has partnered with the Carcinoid Cancer Foundation and Self Care Catalysts to provide a digital patient support tool known as the Carcinoid NETs Health Storylines mobile and web application. Sponsored in part by Ipsen, the…


Lexicon Pharmaceuticals Submits New Drug Application for Telotristat Etiprate

April 3, 2016

Lexicon Pharmaceuticals has submitted a new drug application to the US Food and Drug Administration (FDA) for Telotristat Etiprate for the treatment of carcinoid syndrome.

For patients with carcinoid syndrome who are no longer responding to the current…


Breaking News about PRRT

March 23, 2016

Advanced Accelerator Applications (AAA) announced  on March 23, 2016 that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program Lutathera is being made available…


Finding an Outlet in the Face of Rare Cancers by Diane Reidy Lagunes, MD

March 16, 2016

Carcinoid/neuroendocrine cancer specialist Dr. Diane Reidy Lagunes, medical oncologist at Memorial Sloan Kettering Cancer Center in New York City, explains how her patients inspire her as a physician and why she participates in Cycle for Survival


Rare Disease Day 2016

February 29, 2016

February 29, 2016 is Rare Disease Day, an annual, international advocacy day to bring widespread recognition of rare diseases as a global health challenge. The Carcinoid Cancer Foundation is proud to be a Rare Disease Day Partner.  Learn more here:


FDA Approves Afinitor for Gastrointestinal and Lung Neuroendocrine Tumors

February 26, 2016

Breaking News!  Afinitor Receives FDA Approval in GI and Lung NETs.…/fda-approves-new-indication-nova…


Neuroendocrine Cancer Experts Hold Inaugural Summit in Colorado, February 25-26, 2016

February 24, 2016

Over 30 neuroendocrine tumor (NET) expert physicians and researchers from the United States and Europe will come together for a two-day summit, February 25 and 26, 2016, in Beaver Creek, Colorado, where they will share knowledge and experience that …


$15 Million Gift Awarded to NET Research Foundation from Margie and Robert E. Petersen Foundation

February 23, 2016

An extraordinary gift of $15 million to the Neuroendocrine Tumor Research Foundation in Boston, Massachusetts, from the Margie and Robert E. Petersen Foundation was announced  on February 4, 2016, World Cancer Day, by Ron Hollander, Executive Director…


Luncheon with the Experts in NYC, December 6

November 6, 2015

Carcinoid and neuroendocrine tumor (NET) patients have a unique opportunity to hear from three medical experts during Lunch with the Experts in New York City onSunday, December 6, 2015. This special program was initiated and is sponsored by theBig Apple